CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

News Charles River Laboratories International, Inc. Deutsche Boerse AG

Stocks

RV6

US1598641074

Biotechnology & Medical Research

Real-time Estimate Tradegate 18:41:43 18/08/2026 BST			5-day change	1st Jan Change
243.70 ^EUR	+1.16%		+2.76%	+43.09%

08-13	Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing	MT
08-10	TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating	MT

All News

Mentions Relevance

08-13	Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing	MT
08-10	TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating	MT
08-10	Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating	MT
08-06	Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing	MT
08-06	Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220	MT
08-06	RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating	MT
08-06	Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating	MT
08-06	JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180	MT
08-05	Top Midday Gainers	MT
08-05	Charles River Laboratories International, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-05	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
08-05	Charles River Laboratories International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026	CI
08-05	Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Fall; Lifts 2026 Guidance	MT
08-05	Charles River Laboratories International, Inc. Updates Earnings Guidance for 2026	CI
08-05	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11	MT
08-05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M	MT
08-05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Adjusted EPS $3.02, vs. FactSet Est of $2.74	MT
08-05	Charles River lifts profit forecast on improving biotech demand	RE
08-05	Charles River: Q2 Earnings Snapshot	AQ
08-05	Charles River Laboratories Announces Second-Quarter 2026 Results	BU
07-15	Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call	BU
07-13	BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220	MT
07-13	Baird Adjusts Charles River Laboratories International Price Target to $255 From $213, Maintains Outperform Rating	MT
07-13	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
07-13	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI